We are a late clinical-stage biopharmaceutical company working to develop the first ophthalmic formulation of bevacizumab approved by the U.S. Food and Drug Administration, or FDA, for use in retinal indications.
Last Closing Price
January 29, 2021
H.C. WAINWRIGHT & CO., INC.
This offering is no longer available
Sign Up to participate in future offerings
To view the prospectus for Outlook Therapeutics, or any offering listed on ClickIPO,
download the ClickIPO app...
or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC P. O. Box 21154, Mesa, AZ 85277